JP2022521410A - 最適化されたワクチン組成物およびその製造方法 - Google Patents

最適化されたワクチン組成物およびその製造方法 Download PDF

Info

Publication number
JP2022521410A
JP2022521410A JP2021549435A JP2021549435A JP2022521410A JP 2022521410 A JP2022521410 A JP 2022521410A JP 2021549435 A JP2021549435 A JP 2021549435A JP 2021549435 A JP2021549435 A JP 2021549435A JP 2022521410 A JP2022521410 A JP 2022521410A
Authority
JP
Japan
Prior art keywords
antigen
vaccine
antigens
clade
vaccine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521410A5 (enExample
Inventor
ジェイコブ グランヴィル，
サラ アイブズ，
マイケル イザキー，
サウサン ユーセフ，
ジャン－フィリップ ビュルケルト，
Original Assignee
センティヴァックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センティヴァックス， インコーポレイテッド filed Critical センティヴァックス， インコーポレイテッド
Publication of JP2022521410A publication Critical patent/JP2022521410A/ja
Publication of JP2022521410A5 publication Critical patent/JP2022521410A5/ja
Priority to JP2025056539A priority Critical patent/JP2025098224A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021549435A 2019-02-21 2020-02-21 最適化されたワクチン組成物およびその製造方法 Pending JP2022521410A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025056539A JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962808760P 2019-02-21 2019-02-21
US62/808,760 2019-02-21
US201962817902P 2019-03-13 2019-03-13
US62/817,902 2019-03-13
PCT/US2020/019367 WO2020172635A1 (en) 2019-02-21 2020-02-21 Optimized vaccine compositions and methods for making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025056539A Division JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Publications (2)

Publication Number Publication Date
JP2022521410A true JP2022521410A (ja) 2022-04-07
JP2022521410A5 JP2022521410A5 (enExample) 2023-09-07

Family

ID=72145134

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021549435A Pending JP2022521410A (ja) 2019-02-21 2020-02-21 最適化されたワクチン組成物およびその製造方法
JP2025056539A Pending JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025056539A Pending JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Country Status (5)

Country Link
US (1) US20220088175A1 (enExample)
EP (2) EP3927372A4 (enExample)
JP (2) JP2022521410A (enExample)
CN (1) CN113747915A (enExample)
WO (1) WO2020172635A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217714B (zh) * 2022-10-14 2024-03-15 华中农业大学 一种全猪源pedv单克隆抗体及其抗原表位
WO2024102923A1 (en) * 2022-11-09 2024-05-16 Centivax, Inc. Low dose vaccine compositions
CN121729242A (zh) * 2023-04-20 2026-03-24 森蒂瓦克斯公司 疫苗组合物及其用途
CN119219767B (zh) * 2023-06-29 2025-05-27 华中农业大学 两株全猪源pedv单克隆中和抗体及其用途
WO2025235418A1 (en) * 2024-05-05 2025-11-13 National Health Research Institutes Virus-like particle, preparation method thereof, and use thereof in preparing vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018073340A1 (en) * 2016-10-19 2018-04-26 Redbiotec Ag Influenza virus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425611B2 (en) * 2003-03-28 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Immunogenic HIV-1 multi-clade, multivalent constructs and methods of their use
EP2023952B1 (en) * 2006-05-18 2015-07-15 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CN103826657A (zh) * 2011-04-04 2014-05-28 衣阿华大学研究基金会 改进疫苗免疫原性的方法
AU2012271336B2 (en) * 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
US9884893B2 (en) * 2012-05-21 2018-02-06 Distributed Bio, Inc. Epitope focusing by variable effective antigen surface concentration
JP2018504412A (ja) * 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
WO2016205389A1 (en) * 2015-06-15 2016-12-22 Emory University Multivalent enterovirus vaccine compositions and uses related thereto
KR20190093816A (ko) * 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018073340A1 (en) * 2016-10-19 2018-04-26 Redbiotec Ag Influenza virus vaccine

Also Published As

Publication number Publication date
EP4729125A2 (en) 2026-04-22
WO2020172635A1 (en) 2020-08-27
JP2025098224A (ja) 2025-07-01
US20220088175A1 (en) 2022-03-24
EP3927372A4 (en) 2023-01-25
EP3927372A1 (en) 2021-12-29
CN113747915A (zh) 2021-12-03

Similar Documents

Publication Publication Date Title
Pillet et al. Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial
Webster et al. Continuing challenges in influenza
JP2025098224A (ja) 最適化されたワクチン組成物およびその製造方法
US10793834B2 (en) Live-attenuated virus and methods of production and use
Dundon et al. Progressive truncation of the Non-Structural 1 gene of H7N1 avian influenza viruses following extensive circulation in poultry
WO2012047941A2 (en) Hemagglutinin polypeptides, and reagents and methods relating thereto
JP2016509609A (ja) Ｈ５インフルエンザのヒトへの適応
WO2019191261A1 (en) Methods of generating broadly protective vaccine compositions comprising neuraminidase
CA2811023A1 (en) Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
Rimmelzwaan et al. Immune responses to infection with H5N1 influenza virus
CN103328629A (zh) 针对大流行性甲型流感病毒h1n1的新型疫苗
JP7479424B2 (ja) 改変インフルエンザヘマグルチニンポリペプチドの修飾
Nishiyama et al. Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses
JP2021519084A (ja) ヘマグルチニンを含む広範に防御的なワクチン組成物を生成する方法
US10301359B2 (en) Human adaptation of H3 influenza
Arevalo Of Mice, Ferrets, And Men: From Original Antigenic Sin To A New Universal Influenza Virus Vaccine Candidate
EA051755B1 (ru) Модификация сконструированных полипептидов гемагглютинина вируса гриппа

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328